Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The goal of this campaign is to reduce unnecessary ED visits by providing patients who are high ED utilizers (with a visit of any acuity) with alternative resources to manage their health outside of the ED. In this campaign, patients will be randomized to receive one of two types of outreach following discharge aligned with the goal. Outreach may occur via (1) a phone call from a Geisinger Community Health Worker (CHW) or Community Medical Assistant (CMA); current standard practice or (2) an interactive chatbot message providing similar information and questions to those provided by the CHW/CMA. The study team will measure whether ED use differs across patients in different outreach conditions. The study team will also examine whether patients followed through on the message-specific calls to action in the messages differently across conditions.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Community Health Worker/Community Medical Assistant Outreach | Active Comparator | Patients will receive outreach from a community health worker or a community medical assistant, as is current standard practice, including guidance about ED-alternative resources to encourage care outside of the ED when appropriate. |
|
| SMS Chatbot Messages | Experimental | Patients will be sent interactive SMS chatbot messages, including guidance about ED-alternative resources to encourage care outside of the ED when appropriate; patients will not receive outreach from a community health worker or community medical assistant. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Automated interactive messages | Behavioral | High ED utilizers will be sent SMS text messages guiding them through ED-alternative resources, with different guidance (including a follow-up phone call from a healthcare worker) depending on patient responses. |
| Measure | Description | Time Frame |
|---|---|---|
| Return to ED (Y/N) | Patient had a new Geisinger ED encounter after being discharged | Within 120 calendar days following day of discharge |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Successful Patient Contact (Y/N) - 3 days | At least one successful contact between patient and a CMA, a CHW, or a representative at the monitoring center (Y/N) | Within 3 business days following day of discharge |
| Successful Patient Contact (Y/N) - 5 days |
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Amir Goren, PhD | Geisinger Clinic | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Geisinger Health System | Danville | Pennsylvania | 17822 | United States |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot_SAP | Yes | Yes | No | Study Protocol and Statistical Analysis Plan | Jan 29, 2025 | Jan 29, 2025 | Prot_SAP_000.pdf |
Not provided
| ID | Term |
|---|---|
| D004630 | Emergencies |
| ID | Term |
|---|---|
| D020969 | Disease Attributes |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
Not provided
Not provided
| ID | Term |
|---|---|
| D003143 | Communication Devices for People with Disabilities |
| D019002 | CD56 Antigen |
| ID | Term |
|---|---|
| D012656 | Self-Help Devices |
| D004864 | Equipment and Supplies |
| D019006 | Neural Cell Adhesion Molecules |
| D015816 | Cell Adhesion Molecules, Neuronal |
Not provided
Not provided
Not provided
Not provided
Not provided
Patients will be aware of their own messages but will not be aware of other messages.
Not provided
|
| Live outreach | Behavioral | High ED utilizers will be called (and possibly visited) by a CHW/CMA guiding them through ED-alternative resources. |
|
|
At least one successful contact between patient and a CMA, a CHW, or a representative at the monitoring center (Y/N)
| Within 5 business days following day of discharge |
| Time to Contact | Time to successful patient contact by monitoring center, CMA, or CHW | Within 30 calendar days following day of discharge |
| Patient replied via SMS text (Y/N) to Artera chatbot | Patient responded to the Artera chatbot at least once (Y/N) | Within 7 calendar days following first Artera outreach |
| ED Use (Y/N) | Patient had a new Geisinger ED encounter after being discharged | Within 30 calendar days following day of discharge |
| ED Use After Outreach (Y/N) | Patient had a new Geisinger ED encounter after receiving outreach | Within 30 calendar days following day of outreach by Artera, CMA, or CHW |
| D015815 | Cell Adhesion Molecules |
| D008562 | Membrane Glycoproteins |
| D006023 | Glycoproteins |
| D006001 | Glycoconjugates |
| D002241 | Carbohydrates |
| D011506 | Proteins |
| D000602 | Amino Acids, Peptides, and Proteins |
| D008565 | Membrane Proteins |
| D000945 | Antigens, Differentiation, T-Lymphocyte |
| D000943 | Antigens, Differentiation |
| D000954 | Antigens, Surface |
| D000941 | Antigens |
| D001685 | Biological Factors |
| D015415 | Biomarkers |